The use of genetic analysis of liquid biopsy for predicting and monitoring ofresponse to therapies and tumor evolution in patients with melanoma
2021/43/B/NZ7/01812
Keywords
Descriptors
- NZ7_014: Farmacja, farmakoterapia, farmakologia
- NZ2_002: Genomika, transkryptomika i epigenomika
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach
Voivodeship: mazowieckie
Principal investigator (from the host institution)
Number of co-investigators in the project: 11
Call
OPUS 22 – announced on 2021-09-15
- Amount awarded
- 1 414 772 PLN
- Project start date
- 2022-07-18
- Project end date
- 2027-04-17
- Project duration
- 57 months (the same as in the proposal)
- Project status
- Pending project
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Melanoma genomics – will we go beyond BRAF in clinics?
- Authors:
- Justyna Mirek, Wiesław Bal, Magdalena Olbryt
- Academic press:
- Journal of Cancer Research and Clinical Oncology (year: 2024, volume: 151, pages: 433), Publisher: Springer
- Status:
- Published
- DOI:
- 10.1007/s00432-024-05957-2 – link to the publication